Search clinical trials for: Vortioxetine (Lu AA21004)

Total 359 results

H. Lundbeck A/S

Completed

Pharmacokinetic Properties of Vortioxetine in Healthy Young Chinese Men and Women

Pharmacokinetics

China
H. Lundbeck A/S

Completed

Efficacy of Vortioxetine (Lu AA21004) in the Prevention of Relapse of Major Depressive Episodes

Major Depressive Disorder
H. Lundbeck A/S

Completed

Open-label Safety Extension Study of 5 and 10 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in Adults

Major Depressive Disorder
H. Lundbeck A/S

Completed

Investigating the Effect of Vortioxetine in Adult ADHD Patients

Attention Deficit Hyperactivity Disorder

United States
H. Lundbeck A/S

Completed

Efficacy Study of Vortioxetine on Cognitive Dysfunction in Adult Patients With Major Depressive Disorder (FOCUS)

Major Depressive Disorder
H. Lundbeck A/S

Completed

Open-label Safety Extension Study of 2.5, 5 and 10 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in Adults

Major Depressive Disorder
H. Lundbeck A/S

Completed

Exploratory Study of the Effects of Vortioxetine (Lu AA21004) on Cognition and Blood Oxygen Level Dependent (BOLD) Functional Magnetic Resonance Imaging (fMRI) Signals in Subjects Remitted From Depression and in Controls

Depression

United Kingdom
H. Lundbeck A/S

Completed

Open-label Safety Extension Study of 15 and 20 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in Adults

Major Depressive Disorder
Takeda

Completed

Efficacy Study of Vortioxetine (Lu AA21004) for Treatment of Major Depressive Disorder

Major Depressive Disorder

Japan
University of Pennsylvania

Recruiting

Tau PET/CT Imaging in the Mismatch Prospective Cohort Study (MPC-TAU) (MCP)

Alzheimer's Disease

United States
H. Lundbeck A/S

Completed

A Study of Vortioxetine (Lu AA21004) in Comparison to Agomelatine in Adults Suffering From Major Depression With Inadequate Response to Previous Medication (REVIVE)

Major Depressive Disorder
H. Lundbeck A/S

Completed

Efficacy of Vortioxetine on Cognitive Dysfunction in Patients With Partial or Full Remission of Major Depressive Disorder

Major Depressive Disorder

Finland, Germany, Serbia, Slovakia, Estonia
Takeda

Completed

A Bioequivalence Study of the Lu AA21004 20 mg and 2×10 mg Tablets

Healthy Adult Participants

Japan
H. Lundbeck A/S

Completed

Relapse-prevention Study With Lu AA21004 (Vortioxetine) in Patients With Generalized Anxiety Disorder

Generalized Anxiety Disorder

Chile, Argentina, Colombia, Costa Rica, Estonia, Finland, France, Hungary, Peru, Russian Federation, South Africa
Takeda

Completed

Long-Term Extension Study of Lu AA21004 in Participants With Major Depressive Disorder

Major Depressive Disorder

Japan
H. Lundbeck A/S

Completed

Pharmacokinetic Properties of Lu AA21004 (Vortioxetine) in Healthy Young Chinese Men and Women

Healthy

China
H. Lundbeck A/S
Takeda

Completed

Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 12 to 17 Years With Major Depressive Disorder (MDD)

Depressive Disorder, Major

United States, Bulgaria, Canada, Colombia, Estonia, France, Germany, Hungary, Italy, Korea, Republic of, Latvia, Mexico, Poland, Russian Federation, Serbia, South Africa, Spain, Ukraine, United Kingdom
H. Lundbeck A/S
Takeda

Completed

Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Participants Aged 7 to 11 Years With Major Depressive Disorder (MDD)

Depressive Disorder, Major

Korea, Republic of, United States, Hungary, Poland, Spain, Serbia, Estonia, Bulgaria, Mexico, Russian Federation, Ukraine, Canada, Colombia, France, Germany, Israel, Italy, Latvia, South Africa
Takeda

Completed

Pharmacokinetics, Safety and Tolerability of Vortioxetine in Normal Hepatic Function or Severe Hepatic Impairment

Severe Hepatic Impairment

United States
H. Lundbeck A/S

Completed

Continuation With Vortioxetine in Child and Adolescent Patients With Major Depressive Disorder (MDD) From 7 to 17 Years of Age

Depressive Disorder, Major

Spain, Hungary, Russian Federation, Bulgaria, Estonia, France, Germany, Italy, Latvia, Poland, Serbia, South Africa, United Kingdom
Takeda

Completed

A Phase 3 Study of Lu AA21004 in Patients With Major Depressive Disorder

Major Depressive Disorder

Japan
H. Lundbeck A/S

Completed

Efficacy of Vortioxetine Versus Escitalopram on Cognitive Function in Patients With Inadequate Response to Current Antidepressant Treatment of Major Depressive Disorder

Major Depressive Disorder

Finland, Germany, Serbia, Slovakia
H. Lundbeck A/S

Completed

Randomised Placebo-controlled Venlafaxine-referenced Study of Efficacy and Safety of 5 and 10 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder in Adults

Major Depressive Disorder
H. Lundbeck A/S

Completed

Study of Vortioxetine (Lu AA21004) in Major Depressive Disorder in Asian Countries

Major Depressive Disorder
H. Lundbeck A/S

Terminated

Long-term, Open-label, Flexible-dose, Extension Study of Vortioxetine in Child and Adolescent Participants With Major Depressive Disorder (MDD) From 7 to 18 Years of Age

Depressive Disorder, Major

United States, Korea, Republic of, Hungary, Poland, Spain, Serbia, Estonia, Bulgaria, Latvia, Russian Federation, Ukraine, Canada, Colombia, France, Germany, Israel, Italy, Mexico, South Africa, United Kingdom
Takeda
H. Lundbeck A/S

Completed

Efficacy and Safety of Vortioxetine (Lu AA21004) for Treatment of Generalized Anxiety Disorder in Adults.

Generalized Anxiety Disorder

Ukraine, Germany, Romania, Russian Federation, Lithuania, Latvia, Estonia, Poland
Takeda

Completed

Efficacy and Safety Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder

Depressive Disorder, Major

United States
Takeda
H. Lundbeck A/S

Completed

Safety and Tolerability of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder

Major Depressive Disorder

United States, France, United Kingdom, Germany, Malaysia, Serbia, South Africa, Ukraine, Taiwan, Korea, Republic of, Russian Federation, Lithuania, Latvia, Croatia, Australia, Netherlands, Poland
Takeda

Completed

Effects of Vortioxetine (Lu AA21004) on the Concentrations of Selected Neurotransmitters in Healthy Male Adults

Healthy

United States
Takeda
H. Lundbeck A/S

Completed

Efficacy and Safety of Vortioxetine (Lu AA21004) in Treating Adults With Major Depressive Disorder

Major Depressive Disorder

United States, Mexico, Canada
Takeda
H. Lundbeck A/S

Completed

Study of Efficacy and Safety of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder

Generalized Anxiety Disorder

United States
Takeda
H. Lundbeck A/S

Completed

Efficacy Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder

Major Depressive Disorder

France, Ukraine, Germany, Malaysia, South Africa, Korea, Republic of, Russian Federation, Czech Republic, Lithuania, United Kingdom, Latvia, Australia, Netherlands, Poland, Taiwan
Takeda
H. Lundbeck A/S

Completed

An Efficacy and Safety Study of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder

Generalized Anxiety Disorder

United States
Takeda

Completed

Safety and Efficacy Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder

Depressive Disorder, Major

United States
Takeda

Completed

Efficacy and Safety Study of Vortioxetine (Lu AA21004) for Treatment of Major Depressive Disorder

Depressive Disorder, Major

Taiwan, Germany, Hong Kong, Poland, Malaysia, Romania, Serbia, Ukraine, Japan, Finland, Latvia, Croatia, India, Korea, Republic of, Philippines, Russian Federation
H. Lundbeck A/S

Completed

Efficacy of Vortioxetine on Cognitive Dysfunction in Working Patients With Major Depressive Disorder

Major Depressive Disorder

Finland, Germany, Estonia, Lithuania
H. Lundbeck A/S

Completed

Randomised Placebo-controlled Duloxetine-referenced Study of Efficacy and Safety of 15 and 20 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder in Adults

Major Depressive Disorder
Takeda

Completed

Efficacy of Lu AA21004 on Cognitive Dysfunction in Major Depressive Disorder

Depressive Disorder, Major

United States, Ukraine, Germany, Poland, Bulgaria, Finland, Russian Federation
H. Lundbeck A/S

Completed

Randomised Placebo-controlled Duloxetine-referenced Study of Efficacy and Safety of 5 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder in Elderly Patients

Major Depressive Disorder
H. Lundbeck A/S

Terminated

Study to Evaluate the Safety and Tolerability of a New Drug Named Lu AF20513 in Patients With Mild Alzheimer's Disease

Alzheimer Disease

Austria, Finland, Sweden
H. Lundbeck A/S

Completed

An Exploratory Study Investigating Safety, Tolerability and Pharmacokinetics of Ascending Doses of Lu AE04621 in Parkinson Disease Patients

Parkinson Disease

United States
H. Lundbeck A/S

Completed

Study Investigating the Safety and Tolerability of Lu AF88434 in Healthy Young Men

Healthy

Netherlands
H. Lundbeck A/S

Completed

Randomised Placebo-controlled Duloxetine-referenced Efficacy and Safety Study of 2.5, 5 and 10 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder

Major Depressive Disorder
H. Lundbeck A/S

Completed

Bioequivalence Study of Lu AF35700

Healthy

United Kingdom
Takeda

Completed

Vortioxetine (Lu AA21004) 10 and 20 mg for Treatment of Major Depressive Disorder With Sexual Dysfunction

Treatment Outcome

United States, Canada
H. Lundbeck A/S

Completed

Study With Lu AF35700 in Healthy Men and Women in Fasting and Fed State

Healthy

United Kingdom
H. Lundbeck A/S

Completed

Pharmacokinetic Properties of Various Modified Release Tablet Formulations of Lu AF11167

Schizophrenia

United Kingdom
H. Lundbeck A/S

Completed

Absolute Bioavailability of Lu AE58054 in Healthy Subjects

Healthy

United Kingdom
OHSU Knight Cancer Institute
Novartis; Oregon Health and Science University

Not yet recruiting

177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Recurrent Breast Carcinoma | Metastatic Breast Carcinoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Withdrawn

Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine Cancers

Metastatic Adrenal Gland Pheochromocytoma | Stage III Thyroid Gland Medullary Carcinoma AJCC v8 | Stage IV Thyroid Gland Medullary Carcinoma AJCC v8 | Locally Advanced Adrenal Gland Pheochromocytoma | Locally Advanced Paraganglioma | Metastatic Paraganglioma | Metastatic Parathyroid Gland Carcinoma and other conditions

United States

3

Subscribe